of Childhood, Adolescent, and Young Adult Cancers

It has long been recognized that anthracycline chemother-apy can cause early- and late-onset congestive heart fail-ure (CHF) and cardiomyopathy, which may progress to cardiac-specific death (1). Thus, children treated with an-thracycline are monitored during and periodically after therapy. The Children’s Oncology Group (COG) devel